Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...

Researchers say CSF biomarker test correlates with the severity of cognitive decline, independent of other factors, including brain amyloid deposition.

Research supporting the amyloid hypothesis—the idea that Alzheimer's is caused by a buildup of amyloid plaques in the ...

In ‘Doctored’, Charles Piller, a science journalist, details how groupthink and dishonesty steered Alzheimer’s research off ...

There is no cure. Between 1995 and 2021, around $42bn was poured into more than 1,000 clinical trials. Yet only a handful of ...

Aside from the potential curse of long COVID, people who've had the SARS-CoV-2 virus may be more likely to develop high ...

Readers worry that fraud may tarnish the field and slow the race for a cure. Also: Charles Blow’s farewell; treatment for ...

An international trial is testing remternetug in young adults at genetic risk for early-onset Alzheimer’s. The study aims to ...

The finding may open a whole new world in the study of Alzheimer's disease, said biophysicist Aneta Stefanovska.

A new biomarker test developed at the University of Pittsburgh could help doctors doctors detect signs of Alzheimer's years sooner, according to research published Monday in Nature Medicine.